No definition available.
Acute drug-induced interstitial lung disorder
ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
274 |
4. Check minimum number of eventsNone |
274 |
5. Include endpointsNone |
274 |
6. Filter based on genotype QC (FinnGen only) |
271 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Acute drug-induced interstitial lung disorder
based on the number of shared cases.
Similar with more cases:
- Respiratory conditions due to other external agents
- Lung diseases due to external agents
- Diagnoses used for exclusion with ILD
- Other pulmonary diagnosis
- Excluding asthma or asthma-COPD overlap
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2095 | 1174 | 893 |
| Only index persons | 1591 | 915 | 676 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 71.85 | 72.84 | 70.45 |
| Only index persons | 70.45 | 71.25 | 69.35 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 271 | 135 | 136 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.06 |
| Median age at first event (years) | 68.12 | 65.35 | 70.86 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 274
- Matched controls
- 2740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J70.2
ICD-10 Finland
Acute drug-induced interstitial lung disorders
+∞
307.7
274
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
17.5
96.9
92
77
TGC00
NOMESCO Finland
Bronchial lavation
18.3
64.0
55
37
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.5
45.3
79
141
H02AB06
ATC
prednisolone; systemic
7.1
43.5
221
1013
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.9
36.2
80
178
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
13.3
33.1
33
28
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.1
30.2
145
585
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.2
30.2
36
40
GD1AD
NOMESCO Finland
Thorax CT examination
6.6
28.1
50
89
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.4
25.5
58
130
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
4.5
24.2
72
201
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.8
23.8
48
96
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.7
23.2
190
1034
JN4AD
NOMESCO Finland
Body CT examination
4.6
23.1
65
173
H02AB02
ATC
dexamethasone; systemic
4.2
21.3
67
194
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.9
18.9
68
215
A04AA02
ATC
granisetron; systemic, transdermal
5.0
18.3
43
98
R50.9
ICD-10 Finland
Fever, unspecified
3.6
17.8
72
246
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
5.7
17.2
34
66
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.9
17.2
60
185
C03CA01
ATC
furosemide; systemic
2.9
16.6
145
769
C01BD01
ATC
amiodarone; systemic
6.5
16.4
28
47
JN4BD
NOMESCO Finland
Extensive body CT
3.7
16.4
62
202
A03FA01
ATC
metoclopramide; systemic, rectal
3.1
16.3
97
417
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
5.2
16.2
36
78
L03AA13
ATC
pegfilgrastim; parenteral
5.1
15.2
34
74
ZXE00
NOMESCO Finland
One hour or less
2.7
14.2
141
780
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.9
14.2
33
74
J01MA12
ATC
levofloxacin; systemic
2.9
14.2
86
370
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
13.7
13
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.2
13.2
38
101
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
4.5
13.0
34
84
L04AX03
ATC
methotrexate; systemic
3.6
12.8
47
149
XW000
NOMESCO Finland
Bone marrow biopsy
4.8
12.0
28
63
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
11.8
117
633
L04AA13
ATC
[U] leflunomide
9.9
11.7
23
25
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
6.1
11.2
20
35
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.0
11.1
33
90
D70.82
ICD-10 Finland
Drug-induced neutropenia
11.3
11.0
20
19
A07EC01
ATC
sulfasalazine; oral, rectal
3.6
10.9
39
121
WX892
NOMESCO Finland
Monitored bed care
3.8
10.9
35
101
A04AA55
ATC
palonosetron, combinations; systemic
5.3
10.7
22
44
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
10.6
132
782
M04AA01
ATC
allopurinol; systemic
2.7
10.5
67
291
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.9
10.4
33
94
A02BC02
ATC
pantoprazole; systemic
2.6
10.4
211
1539
P01BA02
ATC
hydroxychloroquine; oral
3.4
10.0
39
128
B01AB10
ATC
tinzaparin; parenteral
3.0
10.0
48
179
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
9.9
72
333
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.8
9.8
32
93
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
9.7
53
212
I50.1
ICD-10 Finland
Left ventricular failure
3.7
9.7
33
99
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
15.8
9.6
15
10
L01BA01
ATC
methotrexate; systemic
5.2
9.5
20
41
ZXD05
NOMESCO Finland
Urgent procedure
2.3
9.4
102
565
L04AX01
ATC
azathioprine; systemic
5.3
9.2
19
38
XX3DW
NOMESCO Finland
Time consuming IT work
2.8
9.2
52
211
L03AA14
ATC
lipegfilgrastim; parenteral
8.8
9.2
19
23
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.7
9.2
31
92
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
16.3
9.1
14
9
L04AB01
ATC
etanercept; parenteral
19.4
9.0
13
7
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
5.2
9.0
19
39
TPH07
NOMESCO Finland
Cathetrisation of artery
2.8
8.7
50
205
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
10.5
8.6
16
16
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
8.6
79
405
WZC30
NOMESCO Finland
Teaching
2.5
8.6
62
285
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
7.1
8.5
20
30
ZX120
NOMESCO Finland
Intravenous
2.9
8.5
45
176
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
13.3
8.5
14
11
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.0
8.4
17
20
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.0
8.4
17
20
R06.0
ICD-10 Finland
Dyspnoea
2.2
8.3
102
588
ZXE10
NOMESCO Finland
More than one and less than three hours
2.1
8.2
118
722
PD4CG
NOMESCO Finland
Extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
10.5
8.1
15
15
WF049
NOMESCO Finland
Radiotherapy of metastasis
4.5
8.1
20
47
I50.0
ICD-10 Finland
Congestive heart failure
2.8
8.1
44
175
NHQ40
NOMESCO Finland
Amputation of toe
8.2
8.0
17
22
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.7
8.0
48
201
M05BX04
ATC
denosumab; parenteral
3.4
7.9
29
91
PEF23
NOMESCO Finland
Thrombendarterectomy of femoral artery
9.8
7.9
15
16
I50.9
ICD-10 Finland
Heart failure, unspecified
2.3
7.8
70
353
N03AX16
ATC
[U] pregabalin
2.2
7.8
81
435
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
4.0
7.5
22
59
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.2
7.5
31
105
A41.9
ICD-10 Finland
Sepsis, unspecified
4.1
7.4
21
55
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.4
7.4
28
90
L88
ICPC
Rheumatoid/seropositive arthritis
4.5
7.3
18
42
J70.3
ICD-10 Finland
Chronic drug-induced interstitial lung disorders
+∞
7.3
7
*
D64.9
ICD-10 Finland
Anaemia, unspecified
2.6
7.3
48
210
L04AA01
ATC
[U] ciclosporin
16.3
7.3
11
7
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.0
7.2
21
56
NH3EA
NOMESCO Finland
Feet X-ray examination with load
8.3
7.2
15
19
ZX108
NOMESCO Finland
Inhalation
30.9
7.2
9
*
A02BC01
ATC
omeprazole; systemic
2.1
7.1
94
551
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
2.9
7.1
35
132
C07AB07
ATC
bisoprolol; oral
2.0
7.0
167
1204
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.8
7.0
38
151
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
14.3
6.9
11
8
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
4.0
6.9
20
53
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
3.3
6.8
27
89
WW500
NOMESCO Finland
Blood transfusion
3.7
6.7
22
64
HA1AA
NOMESCO Finland
X-ray mammography
2.9
6.7
32
118
L04AA06
ATC
mycophenolic acid; systemic
9.0
6.6
13
15
L04AD01
ATC
ciclosporin; systemic
9.0
6.6
13
15
N02AA05
ATC
oxycodone; systemic
2.2
6.6
70
376
M01CB01
ATC
sodium aurothiomalate; parenteral
10.4
6.6
12
12
J01MA02
ATC
ciprofloxacin; systemic
1.9
6.5
127
850
PD4DE
NOMESCO Finland
Lower extremity artery ultrasound examination with Doppler method
5.8
6.4
17
31
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.0
6.4
91
545
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
4.0
6.4
18
47
R06AE07
ATC
cetirizine; oral
1.9
6.3
116
757
ZXE20
NOMESCO Finland
More than three and less than five hours
2.3
6.3
54
266
PWG00
NOMESCO Finland
Reoperation on peripheral vessels for thrombosis or embolism
+∞
6.3
6
*
WB133
NOMESCO Finland
Very demanding adjuvant cytostatic therapy
+∞
6.3
6
*
B01AA03
ATC
warfarin; systemic
2.0
6.3
79
453
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.1
80
464
L01CA04
ATC
vinorelbine; systemic
10.4
6.1
11
11
Z51.5
ICD-10 Finland
Palliative care
2.7
6.1
34
137
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
22
27.58
70.33
1.5
1.5
—
—
—
0
0
51
46
13.39
49.90
1.7
1.5
—
—
—
0
0
47
37
15.13
49.87
1.6
1.6
—
—
—
0
0
50
44
13.68
49.67
1.7
1.6
—
—
—
0
0
57
62
11.35
49.24
1.7
1.5
—
—
—
0
0
41
26
18.37
48.76
1.8
1.3
—
—
—
0
0
56
63
10.92
47.16
1.7
1.5
—
—
—
0
0
43
39
12.89
41.69
1.8
1.4
—
—
—
0
0
40
33
14.02
41.07
1.7
1.7
—
—
—
0
0
42
39
12.54
40.07
1.7
1.6
—
—
—
0
0
35
34
11.66
32.23
2.9
5.8
574.83
135.40
iu/ml
—
6
5
42
57
8.52
30.15
1.6
1.3
—
—
—
0
0
89
280
4.23
25.63
2.5
1.9
—
—
—
0
0
29
31
10.34
24.85
1.1
1.2
—
—
—
0
0
87
276
4.15
24.67
2.5
1.8
—
—
—
0
0
44
85
5.98
22.58
2.6
3.0
—
—
—
0
0
105
401
3.62
22.45
2.7
1.9
—
—
—
0
0
31
43
8.00
21.66
4.2
2.7
61.71
59.88
%
0.25
31
43
30
42
7.90
20.78
3.5
2.3
4.37
4.78
e9/l
0.36
30
42
32
20
17.94
20.68
1.9
1.3
—
—
—
0
0
29
14
23.00
20.42
1.8
1.3
—
—
—
0
0
29
14
23.00
20.42
1.8
1.3
—
—
—
0
0
35
60
6.54
20.18
1.6
1.4
—
—
—
0
0
30
18
18.55
19.68
1.8
1.3
—
—
—
0
0
77
259
3.74
19.66
5.1
3.6
—
—
—
0
0
31
49
7.01
19.27
3.4
2.5
16.60
15.42
%
0.55
13
26
22
7
33.98
17.32
1.1
1.1
—
—
—
0
0
200
1284
3.06
15.57
18.5
8.7
4.41
4.19
e9/l
0.71
193
1127
25
43
6.30
14.26
1.4
1.6
—
—
—
0
0
25
43
6.30
14.26
1.4
1.6
—
—
—
0
0
20
13
16.48
12.83
1.6
2.0
—
—
—
0
0
23
28
8.86
11.06
2.8
1.5
88.51
89.80
%
0.42
23
28
165
1072
2.36
10.69
11.1
5.7
1.20
1.21
mmol/l
0.80
159
966
176
1183
2.36
10.43
11.2
6.4
1.21
1.21
mmol/l
0.48
122
999
14
9
16.30
9.13
1.3
1.2
—
—
—
0
0
154
1015
2.18
9.09
6.1
4.4
32.76
35.08
g/l
5.13
148
951
70
335
2.46
8.90
3.3
2.5
22.97
21.21
%
0.52
60
286
28
80
3.78
8.78
1.8
1.7
—
116.67
—
0
6
134
862
2.09
8.14
4.6
3.3
—
—
—
0
0
110
661
2.11
7.98
4.8
3.3
0.34
0.58
e6/l
0.84
98
503
63
302
2.41
7.91
7.9
6.6
1.19
1.07
mmol/l
0.08
50
247
19
30
6.72
7.86
1.4
1.6
—
—
—
0
0
19
30
6.72
7.86
1.4
1.6
—
—
—
0
0
117
727
2.06
7.70
3.2
2.4
54.88
62.77
u/l
0.55
109
667
21
54
4.13
7.58
2.6
2.4
130.33
124.18
g/l
0.41
15
38
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
76
3.52
7.16
3.8
2.4
0.32
0.35
u/ml
0.18
18
41
14
16
9.15
7.14
2.4
1.1
—
—
—
0
0
121
784
1.97
6.90
4.2
3.2
2.34
2.35
mmol/l
0.21
110
685
163
1172
1.96
6.81
26.1
16.1
1.27
1.31
inr
0.31
78
331
82
476
2.03
6.29
3.6
1.7
1.47
1.32
mg/l
0.17
67
366
48
230
2.32
5.95
5.1
3.9
2.39
2.04
mmol/l
0.29
39
184
16
30
5.60
5.94
1.3
1.8
—
—
—
0
0
92
574
1.91
5.64
3.4
2.8
8217.85
8148.03
umol/l
0.00
81
484
40
181
2.42
5.62
2.3
1.6
—
—
—
0
0
15
28
5.60
5.62
1.3
1.3
—
—
—
0
0
29
112
2.78
5.60
2.9
2.7
4.32
4.28
pmol/l
0.05
22
96
177
1359
1.85
5.53
9.2
4.6
6.89
6.81
mmol/l
0.23
167
1284
16
33
5.08
5.52
1.3
1.7
—
—
—
0
0
9
8
11.58
5.33
3.3
8.0
—
—
—
0
0
119
819
1.80
5.26
4.8
3.3
1384.11
1645.14
ng/l
0.46
111
712
211
1743
1.92
4.89
18.1
7.5
79.69
80.38
u/l
0.09
211
1630
15
42
3.72
4.84
1.1
1.5
—
—
—
0
0
18
58
3.25
4.73
1.1
1.3
—
—
—
0
0
185
1478
1.77
4.66
6.6
4.9
3116.20
3084.61
e6/l
—
5
28
22
82
2.83
4.54
5.5
4.1
140.52
148.09
mg/l
0.03
12
65
22
82
2.83
4.54
5.5
4.1
60.23
32.17
mg/l
0.63
12
65
94
627
1.76
4.48
5.5
4.3
0.00
0.00
estimate
-0.00
56
214
10
16
6.44
4.33
2.5
1.6
1.80
6.00
u/field
—
5
5
13
29
4.65
4.30
1.3
1.2
—
—
—
0
0
16
51
3.27
4.28
1.8
1.5
—
—
—
0
0
16
51
3.27
4.28
1.8
1.5
—
—
—
0
0
56
322
1.93
4.28
8.4
6.4
104.77
104.28
mmol/l
0.38
56
322
31
143
2.32
4.18
1.2
1.4
—
—
—
0
0
10
17
6.06
4.17
1.4
1.0
—
—
—
0
0
30
138
2.32
4.07
4.0
3.5
2.80
1.97
mmol/l
0.71
21
101
129
968
1.63
3.82
6.3
4.3
36.19
39.91
ng/l
0.17
107
758
194
1621
1.67
3.65
7.5
4.2
19.91
13.51
mm/h
4.70
183
1476
137
1052
1.60
3.64
3.0
2.5
—
—
—
0
0
10
21
4.90
3.59
1.2
1.3
—
—
—
0
0
31
153
2.16
3.57
3.9
3.3
4.96
5.12
kpa
0.50
31
148
118
878
1.60
3.55
3.4
2.7
206.69
134.16
ug/l
1.45
111
795
16
58
2.87
3.48
1.1
1.1
—
—
—
0
0
115
854
1.60
3.47
5.7
4.4
—
—
—
0
0
17
64
2.77
3.46
1.6
1.4
0.02
0.02
iu/ml
—
5
15
12
32
3.87
3.43
1.7
1.5
31.50
32.91
pg
0.47
12
32
36
196
1.96
3.21
3.7
3.0
4.81
4.21
kpa
1.00
36
188
140
1102
1.55
3.21
5.5
4.2
0.00
0.00
estimate
-0.00
58
211
138
1085
1.55
3.16
5.6
4.2
0.00
0.00
estimate
0.50
63
243
138
1090
1.54
3.07
6.9
5.6
0.00
0.00
estimate
-0.00
58
224
13
45
2.98
3.07
1.1
1.1
—
—
—
0
0
16
64
2.59
2.93
1.3
1.8
—
—
—
0
0
9
22
4.19
2.90
1.1
1.1
—
—
—
0
0
7
14
5.10
2.74
1.0
1.0
—
—
—
0
0
6
11
5.55
2.55
1.2
1.7
—
—
—
0
0
6
11
5.55
2.55
1.2
1.7
—
—
—
0
0
9
27
3.41
2.41
1.3
1.7
—
—
—
0
0
9
27
3.41
2.41
1.3
1.7
—
—
—
0
0
9
27
3.41
2.41
1.3
1.7
—
—
—
0
0
6
12
5.08
2.41
1.2
1.7
—
—
—
0
0
16
71
2.33
2.39
1.4
1.2
—
—
—
0
0
7
17
4.20
2.37
1.1
1.1
—
—
—
0
0
7
17
4.20
2.37
1.1
1.0
—
—
—
0
0
51
340
1.61
2.32
1.4
1.3
94.40
14.35
u/ml
1.54
14
125
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
16
73
2.27
2.26
1.4
1.2
—
—
—
0
0
7
19
3.75
2.16
4.6
3.9
—
—
—
0
0
71
520
1.49
2.13
2.1
1.8
478.61
442.20
pmol/l
0.64
57
426
183
1599
1.43
2.08
4.9
3.9
15.14
14.97
pmol/l
0.30
160
1409
20
105
1.98
2.01
1.5
1.2
1090.21
220.30
u/ml
0.61
20
95
13
57
2.34
2.01
1.3
1.2
—
—
—
0
0
125
1035
1.38
1.88
3.1
2.6
—
—
—
0
0
24
139
1.80
1.82
2.7
1.7
—
—
—
0
0
7
23
3.10
1.81
1.1
1.2
—
—
—
0
0
11
47
2.40
1.80
1.5
1.5
—
—
—
0
0
6
18
3.38
1.75
1.2
1.1
—
—
—
0
0
78
603
1.41
1.74
2.7
2.1
3.61
3.28
mg/l
0.44
72
511
111
917
1.35
1.64
2.9
2.2
80.62
78.23
nmol/l
0.39
100
797
5
14
3.62
1.62
1.4
1.2
—
—
—
0
0
5
14
3.62
1.62
1.4
1.2
—
—
—
0
0
62
466
1.43
1.61
4.2
3.1
2.50
2.45
mmol/l
1.07
54
410
8
33
2.47
1.55
2.8
4.2
—
—
—
0
0
5
15
3.37
1.53
1.4
1.2
—
—
—
0
0
5
15
3.37
1.53
1.4
1.2
—
—
—
0
0
5
15
3.37
1.53
1.4
1.2
—
—
—
0
0
58
437
1.42
1.49
6.2
3.9
957.43
149.45
ng/l
0.55
52
366
18
104
1.78
1.41
7.2
4.4
1.94
1.56
%
0.51
18
99
7
29
2.45
1.40
1.3
1.0
—
—
—
0
0
17
98
1.78
1.34
1.4
1.3
—
—
—
0
0
36
253
1.49
1.33
1.4
1.4
—
—
—
0
0
193
2079
0.76
1.26
4.4
4.8
4.46
4.52
mmol/l
0.31
174
1903
48
361
1.40
1.25
1.4
1.3
63.01
41.62
iu/ml
0.43
19
114
62
488
1.35
1.23
1.8
1.8
1125.19
1190.25
nmol/l
0.26
47
374
199
2132
0.76
1.22
4.9
5.5
2.60
2.63
mmol/l
0.15
176
1936
5
19
2.66
1.22
1.4
3.1
—
—
—
0
0
15
86
1.79
1.21
9.7
2.1
37.03
37.73
g/l
0.19
15
77
53
674
0.74
1.21
4.1
4.7
21.63
20.90
%
0.11
29
346
11
57
1.97
1.18
1.7
1.8
—
—
—
0
0
226
2122
1.37
1.18
37.4
16.3
24.48
24.99
mg/l
0.10
215
1706
30
209
1.49
1.17
2.1
2.3
36.56
32.54
u/l
0.19
25
172
192
2062
0.77
1.15
4.4
4.8
1.42
1.47
mmol/l
0.90
172
1869
145
1289
1.27
1.14
4.0
3.2
85.26
52.21
u/l
1.52
138
1169
196
2094
0.78
1.08
5.2
5.0
6.24
6.07
mmol/l
0.68
170
1898
185
1990
0.78
1.08
4.0
4.3
1.30
1.26
mmol/l
0.41
163
1791
11
61
1.84
1.00
1.1
1.4
261.20
303.78
ug/g
—
5
37
50
396
1.32
0.96
4.3
3.0
0.51
1.24
e6/l
2.11
36
230
12
70
1.75
0.94
1.6
1.3
0.24
0.24
g/l
0.03
12
70
19
126
1.55
0.94
3.7
2.8
0.70
0.66
%
0.15
19
126
15
94
1.63
0.92
9.7
2.0
10.11
10.57
g/l
0.17
15
84
6
28
2.17
0.92
1.0
1.2
—
—
—
0
0
15
95
1.61
0.89
9.7
2.1
3.21
3.06
g/l
0.25
15
86
19
129
1.51
0.86
3.7
2.8
0.95
1.05
%
0.42
19
129
33
251
1.36
0.83
5.1
2.9
6.77
8.83
umol/l
0.68
26
221
190
2014
0.82
0.80
6.9
6.4
42.36
40.79
mmol/mol
1.22
170
1854
7
39
1.82
0.73
1.1
1.2
—
—
—
0
0
46
376
1.27
0.72
4.5
3.2
1.42
2.20
e6/l
0.71
32
213
24
179
1.37
0.69
5.8
3.8
123.37
84.90
ng/l
1.09
19
156
15
102
1.50
0.69
9.7
2.0
6.89
7.47
g/l
0.86
15
93
15
102
1.50
0.69
9.7
2.0
3.72
3.63
g/l
0.08
15
93
15
102
1.50
0.69
9.7
2.0
—
—
—
0
0
34
274
1.27
0.60
2.5
4.2
10.44
52.74
ug/l
0.83
26
235
0
21
0.00
0.60
0.0
1.0
—
566.46
—
0
13
0
21
0.00
0.60
0.0
1.0
—
36.02
—
0
12
6
35
1.73
0.58
1.3
1.3
—
—
—
0
0
11
73
1.53
0.57
1.5
1.2
—
—
—
0
0
8
55
1.47
0.56
2.0
1.5
—
—
—
0
0
41
485
0.82
0.54
3.3
3.2
0.90
0.78
ug/l
0.31
28
338
6
98
0.60
0.53
1.3
2.0
—
—
—
0
0
76
845
0.86
0.49
5.3
5.4
2.38
2.83
ug/l
0.30
61
744
52
590
0.85
0.44
1.6
1.7
1.58
1.32
mmol/l
1.26
37
486
226
2321
0.85
0.42
51.2
23.8
37.77
39.78
%
4.88
212
2164
203
1956
1.15
0.42
5.8
4.7
2.08
1.99
mu/l
0.19
180
1735
25
302
0.81
0.41
16.8
8.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
21
170
1.25
0.38
1.9
1.6
1.66
1.65
%
0.04
14
141
8
115
0.69
0.38
1.8
1.8
—
—
—
0
0
66
598
1.14
0.36
1.6
1.6
19.92
21.31
nmol/l
0.31
59
495
50
445
1.15
0.36
1.2
1.2
0.58
1.42
u/ml
—
9
120
83
766
1.12
0.34
3.7
3.8
8.68
10.41
mg/mmol
0.26
51
484
6
88
0.67
0.33
1.3
1.9
—
—
—
0
0
6
46
1.31
0.33
2.3
1.3
—
—
—
0
0
22
188
1.19
0.26
9.4
2.9
55.18
58.96
ml/min/173m2
0.34
11
76
12
97
1.25
0.23
2.5
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.17
0.21
1.8
2.7
108.40
106.05
mmol/l
—
5
43
0
13
0.00
0.21
0.0
1.1
—
1.21
—
0
8
6
50
1.20
0.20
3.5
5.1
20.25
32.80
mg/l
—
6
32
199
2028
0.93
0.17
35.3
15.5
72.30
74.99
ml/min/173m2
1.02
187
1666
221
2243
0.92
0.17
37.8
19.2
138.89
139.70
mmol/l
3.37
214
2179
11
92
1.20
0.16
1.0
1.0
—
—
—
0
0
222
2246
0.94
0.12
38.7
19.3
4.01
4.00
mmol/l
0.22
215
2182
223
2255
0.94
0.11
42.0
19.4
89.96
81.06
umol/l
1.61
223
2255
11
124
0.88
0.09
1.2
1.3
—
42.19
—
0
8
24
256
0.93
0.08
1.5
1.4
—
—
—
0
0
56
541
1.04
0.07
3.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
5.8
—
227.37
—
0
8
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
5
49
1.02
0.00
1.0
2.2
—
—
—
0
0
97
970
1.00
-0.00
2.1
2.0
92.13
94.57
pmol/l
0.27
51
481
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1363.40
—
0
5
6
60
1.00
-0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
89
1.01
-0.00
1.9
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD | 2.16 [1.79, 2.61] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.097 |
During the follow-up period (1.1.1998 — 31.12.2019), 543 out of 1003 females with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD | 3.019 [2.39, 3.81] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.103 |
During the follow-up period (1.1.1998 — 31.12.2019), 468 out of 739 males with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.
Mortality risk
Mortality risk for people of age
years, who have ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.208% | 0.651% |
| 5 | 1.326% | 4.207% |
| 10 | 3.024% | 10.044% |
| 15 | 5.758% | 18.972% |
| 20 | 10.277% | 30.484% |
Relationships between endpoints
↥Index endpoint: ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD – Acute drug-induced interstitial lung disorder
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data